Combining Cyramza with IMFINZI® (durvalumab) was safe and effective in a small trial that included gastric cancer patients.
Pieris and Eli Lilly have partnered to test a combination of Cyramza, paclitaxel and Pieris’ novel bispecific antibody in HER2-positive gastric cancer.
In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.
A recent trial of a combination of Stivarga and Opdivo showed better activity than either drug alone in patients with gastric cancer.
New clinical trials will examine the use of the drug DFMO for preventing gastric cancer in people with the H. Pylori infection